Given their excellent cardiovascular safety and efficacy in randomised clinical trials, SGLT2 inhibitors have been the subject of a growing number of preclinical studies investigating their effect on myocardial infarct size, representing an emerging ‘bedside-to-bench’ approach [12]. This evidence concerns the gene SLC5A2 and myocardial infarction.